FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103226055> ?p ?o ?g. }

• W2103226055 endingPage "1077" @default.
• W2103226055 startingPage "1070" @default.
• W2103226055 abstract "Background Patients with idiopathic rapid-eye-movement sleep behaviour disorder (IRBD) may develop neurodegenerative conditions associated with substantia nigra dysfunction such as Parkinson's disease. In patients with Parkinson's disease, 123I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)-nortropane (123I-FP-CIT) SPECT detects striatal dopamine dysfunction resulting from nigral pathology whereas transcranial sonography (TCS) shows increased substantia nigra echogenic size, even before parkinsonism is clinically evident. We postulated that these neuroimaging changes could occur in a proportion of IRBD individuals who might then be at increased risk for development of a neurodegenerative disorder associated with substantia nigra dysfunction. Methods In our prospective study, we identified patients with IRBD from individuals referred to our sleep disorders centre in Barcelona, Spain. At baseline, we assessed dopamine transporter uptake by use of 123I-FP-CIT SPECT, and estimated echogenicity of the substantia nigra by use of TCS. After a follow-up of 2·5 years, participants were clinically assessed to establish whether they had developed neurodegenerative syndromes. Data were compared with those of matched healthy controls. Findings 43 individuals with IRBD agreed to participate in the study. We found reduced 123I-FP-CIT binding in the striatum (p=0·045) in 17 (40%) of 43 participants compared with 18 controls, and substantia nigra hyperechogenicity in 14 (36%) of 39 participants with IRBD, compared with 16 (11%) of 149 controls (p=0·0002). Tracer uptake reduction was more pronounced in the putamen than it was in the caudate nucleus. 27 (63%) participants had reduced 123I-FP-CIT binding or substantia nigra hyperechogenicity at baseline. Eight (30%) of these participants developed a neurodegenerative disorder (five Parkinson's disease, two dementia with Lewy bodies, and one multiple system atrophy). Individuals with normal neuroimaging results remained disease-free. Sensitivity of combined 123I-FP-CIT SPECT and TCS to predict conversion to synucleinopathy after 2·5 years was 100% and specificity was 55%. Interpretation In patients with IRBD, 123I-FP-CIT SPECT and TCS can detect subclinical changes much the same as those typically seen in patients with early Parkinson's disease. Decreased striatal 123I-FP-CIT binding and substantia nigra hyperechogenicity might be useful markers to identify individuals at increased risk for development of synucleinopathies. Funding None. Patients with idiopathic rapid-eye-movement sleep behaviour disorder (IRBD) may develop neurodegenerative conditions associated with substantia nigra dysfunction such as Parkinson's disease. In patients with Parkinson's disease, 123I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)-nortropane (123I-FP-CIT) SPECT detects striatal dopamine dysfunction resulting from nigral pathology whereas transcranial sonography (TCS) shows increased substantia nigra echogenic size, even before parkinsonism is clinically evident. We postulated that these neuroimaging changes could occur in a proportion of IRBD individuals who might then be at increased risk for development of a neurodegenerative disorder associated with substantia nigra dysfunction. In our prospective study, we identified patients with IRBD from individuals referred to our sleep disorders centre in Barcelona, Spain. At baseline, we assessed dopamine transporter uptake by use of 123I-FP-CIT SPECT, and estimated echogenicity of the substantia nigra by use of TCS. After a follow-up of 2·5 years, participants were clinically assessed to establish whether they had developed neurodegenerative syndromes. Data were compared with those of matched healthy controls. 43 individuals with IRBD agreed to participate in the study. We found reduced 123I-FP-CIT binding in the striatum (p=0·045) in 17 (40%) of 43 participants compared with 18 controls, and substantia nigra hyperechogenicity in 14 (36%) of 39 participants with IRBD, compared with 16 (11%) of 149 controls (p=0·0002). Tracer uptake reduction was more pronounced in the putamen than it was in the caudate nucleus. 27 (63%) participants had reduced 123I-FP-CIT binding or substantia nigra hyperechogenicity at baseline. Eight (30%) of these participants developed a neurodegenerative disorder (five Parkinson's disease, two dementia with Lewy bodies, and one multiple system atrophy). Individuals with normal neuroimaging results remained disease-free. Sensitivity of combined 123I-FP-CIT SPECT and TCS to predict conversion to synucleinopathy after 2·5 years was 100% and specificity was 55%. In patients with IRBD, 123I-FP-CIT SPECT and TCS can detect subclinical changes much the same as those typically seen in patients with early Parkinson's disease. Decreased striatal 123I-FP-CIT binding and substantia nigra hyperechogenicity might be useful markers to identify individuals at increased risk for development of synucleinopathies." @default.
• W2103226055 created "2016-06-24" @default.
• W2103226055 creator A5000771869 @default.
• W2103226055 creator A5005995811 @default.
• W2103226055 creator A5008382504 @default.
• W2103226055 creator A5013146660 @default.
• W2103226055 creator A5014930348 @default.
• W2103226055 creator A5016778081 @default.
• W2103226055 creator A5016908006 @default.
• W2103226055 creator A5037217540 @default.
• W2103226055 creator A5041475663 @default.
• W2103226055 creator A5042577463 @default.
• W2103226055 creator A5052833865 @default.
• W2103226055 creator A5054677591 @default.
• W2103226055 creator A5061103007 @default.
• W2103226055 creator A5083727828 @default.
• W2103226055 creator A5086819499 @default.
• W2103226055 creator A5090919913 @default.
• W2103226055 date "2010-11-01" @default.
• W2103226055 modified "2023-10-17" @default.
• W2103226055 title "Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study" @default.
• W2103226055 cites W1884672048 @default.
• W2103226055 cites W1963931649 @default.
• W2103226055 cites W1964440671 @default.
• W2103226055 cites W1965151135 @default.
• W2103226055 cites W1974038177 @default.
• W2103226055 cites W1975287222 @default.
• W2103226055 cites W1976749972 @default.
• W2103226055 cites W1983759421 @default.
• W2103226055 cites W1986783470 @default.
• W2103226055 cites W1991354131 @default.
• W2103226055 cites W2003890389 @default.
• W2103226055 cites W2008560062 @default.
• W2103226055 cites W2011881593 @default.
• W2103226055 cites W2019843791 @default.
• W2103226055 cites W2025298610 @default.
• W2103226055 cites W2027252021 @default.
• W2103226055 cites W2033505604 @default.
• W2103226055 cites W2041184080 @default.
• W2103226055 cites W2046895759 @default.
• W2103226055 cites W2065316442 @default.
• W2103226055 cites W2066219712 @default.
• W2103226055 cites W2067130491 @default.
• W2103226055 cites W2073845471 @default.
• W2103226055 cites W2075751434 @default.
• W2103226055 cites W2078833014 @default.
• W2103226055 cites W2084905311 @default.
• W2103226055 cites W2092462980 @default.
• W2103226055 cites W2093438331 @default.
• W2103226055 cites W2102572922 @default.
• W2103226055 cites W2105217228 @default.
• W2103226055 cites W2106704612 @default.
• W2103226055 cites W2113285169 @default.
• W2103226055 cites W2113436375 @default.
• W2103226055 cites W2114945018 @default.
• W2103226055 cites W2118749287 @default.
• W2103226055 cites W2119398499 @default.
• W2103226055 cites W2119576606 @default.
• W2103226055 cites W2121712380 @default.
• W2103226055 cites W2130252152 @default.
• W2103226055 cites W2134678381 @default.
• W2103226055 cites W2147730137 @default.
• W2103226055 cites W2152841022 @default.
• W2103226055 cites W2153107624 @default.
• W2103226055 cites W2162279729 @default.
• W2103226055 cites W2166263576 @default.
• W2103226055 cites W2210061417 @default.
• W2103226055 cites W2336893408 @default.
• W2103226055 cites W4211253537 @default.
• W2103226055 cites W2112621800 @default.
• W2103226055 doi "https://doi.org/10.1016/s1474-4422(10)70216-7" @default.
• W2103226055 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20846908" @default.
• W2103226055 hasPublicationYear "2010" @default.
• W2103226055 type Work @default.
• W2103226055 sameAs 2103226055 @default.
• W2103226055 citedByCount "339" @default.
• W2103226055 countsByYear W21032260552012 @default.
• W2103226055 countsByYear W21032260552013 @default.
• W2103226055 countsByYear W21032260552014 @default.
• W2103226055 countsByYear W21032260552015 @default.
• W2103226055 countsByYear W21032260552016 @default.
• W2103226055 countsByYear W21032260552017 @default.
• W2103226055 countsByYear W21032260552018 @default.
• W2103226055 countsByYear W21032260552019 @default.
• W2103226055 countsByYear W21032260552020 @default.
• W2103226055 countsByYear W21032260552021 @default.
• W2103226055 countsByYear W21032260552022 @default.
• W2103226055 countsByYear W21032260552023 @default.
• W2103226055 crossrefType "journal-article" @default.
• W2103226055 hasAuthorship W2103226055A5000771869 @default.
• W2103226055 hasAuthorship W2103226055A5005995811 @default.
• W2103226055 hasAuthorship W2103226055A5008382504 @default.
• W2103226055 hasAuthorship W2103226055A5013146660 @default.
• W2103226055 hasAuthorship W2103226055A5014930348 @default.
• W2103226055 hasAuthorship W2103226055A5016778081 @default.
• W2103226055 hasAuthorship W2103226055A5016908006 @default.
• W2103226055 hasAuthorship W2103226055A5037217540 @default.
• W2103226055 hasAuthorship W2103226055A5041475663 @default.

• next